MyFinsight
Home
About
Contact
Back
Income Statement
Inhibikase Therapeutics, Inc. (IKT)
source: myfinsight.com
Download
Download image
Net loss
-$9,915,523
Interest income
$916,755
Loss from operations
-$10,832,278
Total costs and
expenses
$10,832,278
Change in fair value
contingent consideration
$358,420
Research and development
$5,270,967
Selling, general and
administrative
$5,919,731
Back